Two years of follow-up of patients with gastric cancer who were treated with marimastat, an oral matrix metalloproteinase inhibitor, continue to show survival benefit, the Fourth International Gastric Cancer Conference in New York, USA, was told.
The report came as developers British Biotech announced it was terminating trials of the treatment for lung cancer, since no benefit was demonstrated.
|Marimastat shows survival benefit in GI cancer.
|Fourth International Gastric Cancer Conference |
A trial of treatment for pancreatic cancer will continue, although the developers said they could not give any indications of the likely outcome of the trial.
The Phase III trial of the drug as a maintenance treatment for gastric cancer failed to meet its targets when its results were first reported in August 1999. However, it showed enough survival benefit for the trial to be continued.
Two years later patients continued to show survival benefit from having been treated with the drug, researcher John Whiting reported to the New York conference.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com